TOKYO (Reuters) – Fujifilm Holdings Corp said on Wednesday it started a new phase III trial of its anti-influenza drug Avigan in Japan for COVID-19 patients.
The new trial in Japan is targeting patients with early-onset of COVID-19 who have risk factors for progression to severe symptoms, Fujifilm said in a release.
Domestic approval of the drug for COVID-19 was delayed after a health ministry panel said in December that trial data was inconclusive.
(Reporting by Rocky Swift; Editing by Jacqueline Wong)
